NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($1.34) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.80. The biotechnology company had revenue of $0.98 million for the quarter, compared to analysts' expectations of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Aclaris Therapeutics.

Aclaris Therapeutics will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 analysts have issued 1 year target prices for Aclaris Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they expect Aclaris Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 520.7% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

Media coverage about ACRS stock has trended very positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totalling 3,060,000 shares, a drop of 16.6% from the January 15th total of 3,670,000 shares. Based on an average trading volume of 822,800 shares, the short-interest ratio is currently 3.7 days. Approximately 9.2% of the company's stock are short sold. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include MediciNova (MNOV), LifeVantage (LFVN), Theratechnologies (THERF), Agile Therapeutics (AGRX), Cerecor (CERC), Arbutus Biopharma (ABUS), Affimed (AFMD), Theratechnologies (THTX), Abeona Therapeutics (ABEO), Kezar Life Sciences (KZR), Nature's Sunshine Products (NATR), Athersys (ATHX), Five Prime Therapeutics (FPRX), Scpharmaceuticals (SCPH) and Fortress Biotech (FBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Abeona Therapeutics (ABEO), Progenics Pharmaceuticals (PGNX), Anavex Life Sciences (AVXL), Exelixis (EXEL), Amicus Therapeutics (FOLD) and Nabriva Therapeutics (NBRV).

Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include MFN Partners Management LP (9.66%), Renaissance Technologies LLC (6.72%), EcoR1 Capital LLC (5.04%), Broadfin Capital LLC (4.56%), Man Group plc (3.13%) and Geode Capital Management LLC (1.40%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

ACRS stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Alambic Investment Management L.P. and Virtu Financial LLC. View Insider Buying and Selling for Aclaris Therapeutics.

ACRS stock was purchased by a variety of institutional investors in the last quarter, including MFN Partners Management LP, EcoR1 Capital LLC, Renaissance Technologies LLC, Broadfin Capital LLC, Parkman Healthcare Partners LLC, Jacobs Levy Equity Management Inc., Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.45.

Aclaris Therapeutics has a market capitalization of $60.02 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]